Respiree is a health tech company from Singapore that uses artificial intelligence (AI) to help manage diseases throughout patient care. The company has just raised $11.6 million in its Series A funding round. The round was led by We Venture Capital and ClavystBio.
The firm said in a statement on Wednesday that the round also had participation from Adaptive Capital Partners, conversion of note securities from Mayo Clinic’s Mayo Foundation for Medical Research and from existing investors including Greenwillow Capital Management, Seeds Capital, and she1K angel investment.
Respiree will use the new funding to grow its sales team and increase its presence in the U.S., including opening its headquarters in Houston, Texas, at the Texas Medical Center Innovation.
Originally from Singapore, Respiree is working on expanding to more countries around the world.
Right now, its products are available in the U.S., Australia, and many parts of Asia-Pacific.
Recently, Respiree partnered with Roche Diagnostics to start trial programs in the Asia-Pacific region.
The company has also made important partnerships with top healthcare providers to help grow its services in hospitals and home care.
Some of the new money will be used to improve work with current partners and find new business opportunities.
Respiree also plans to enter new markets like the Gulf Cooperation Council countries and Thailand.
“The digitalization of healthcare offers a powerful opportunity to improve outcomes and efficiency—but without the right tools, it risks overwhelming care systems, especially amid workforce shortages,” said Dr. Gurpreet Singh, Founder and Chief Executive Officer of Respiree.
“What we need is better use of data, not just more data. Our AI solutions enable timely interventions, reduce alarm fatigue, and support care quality,
“We’re now focused on scaling these tools to enhance the entire patient journey—from smarter triage to follow-up,” he added.
It is noted that Respiree’s AI platform seeks to support quicker, efficient and precise decision making in various healthcare settings by automating patient monitoring, care pathway management and clinical insight delivery.
“Respiree stands out in the market by providing a patient monitoring AI/machine learning (ML) + hardware solution with incredible performance, but also unmatched understanding and execution of clinical workflow integration,
“Their scientifically validated data and key partnerships position Respiree for a promising scale-up journey driven by an extremely execution-focused team,” said Louise Warme, Head of We Venture Capital.
Meanwhile, Anselm Tan, Digital Health & MedTech Lead, ClavystBio, said the firm’s investment in Respiree is central to its strategy of helping companies scale globally from and through Singapore.
“Their innovative AI-powered monitoring platform is set to enhance patient care and empower clinical teams with actionable insights,
“This further underscores our commitment to accelerating medtech innovations aimed at improving patient outcomes across care settings,” he added.
Dr. Wong Mun Yew, Managing Partner of Oriza Greenwillow Technology Fund, Respiree has achieved much since Greenwillow Capital Management first invested in February 2022 and continued to support the company in the convertible notes last year.
“We are incredibly encouraged by the commercialization of Respiree’s products and services in tier-one markets and look forward to being part of Respiree’s growth as it continues to transform patient care on a global scale,” he added.
Read more- SuperK Raises INR 100 Crore in Funding Led by Binny Bansal and Mithun Sacheti
